Last reviewed · How we verify

ONL Therapeutics — Portfolio Competitive Intelligence Brief

ONL Therapeutics pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hawaii Pacific Health · 1 shared drug class
  2. Jaeb Center for Health Research · 1 shared drug class
  3. Moorfields Eye Hospital NHS Foundation Trust · 1 shared drug class
  4. Novartis · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ONL Therapeutics:

Cite this brief

Drug Landscape (2026). ONL Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/onl-therapeutics. Accessed 2026-06-10.

Related